
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Free Report) – Equities researchers at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of Avalo Therapeutics in a report released on Friday, November 6th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($2.43) per share for the year, up from their previous forecast of ($2.76). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q4 2026 earnings at ($0.55) EPS, Q1 2027 earnings at ($0.54) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.56) EPS, Q4 2027 earnings at ($0.57) EPS and FY2027 earnings at ($2.23) EPS.
Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.25.
View Our Latest Stock Report on Avalo Therapeutics
Avalo Therapeutics Stock Performance
Shares of NASDAQ:AVTX opened at $8.51 on Tuesday. Avalo Therapeutics has a 52-week low of $6.53 and a 52-week high of $24.27. The stock’s fifty day simple moving average is $12.78 and its 200-day simple moving average is $15.72.
Insider Buying and Selling
In other news, CFO Christopher Sullivan sold 12,394 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total value of $202,394.02. Following the completion of the transaction, the chief financial officer directly owned 39,900 shares in the company, valued at approximately $651,567. This represents a 23.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 23,258 shares of company stock worth $395,434. Insiders own 4.46% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. Aberdeen Group plc lifted its stake in Avalo Therapeutics by 83.3% in the third quarter. Aberdeen Group plc now owns 223,908 shares of the company’s stock valued at $3,433,000 after buying an additional 101,739 shares during the last quarter. Fisher Asset Management LLC bought a new stake in Avalo Therapeutics in the 3rd quarter valued at about $4,852,000. Nan Fung Trinity HK Ltd. boosted its stake in Avalo Therapeutics by 161.4% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 189,000 shares of the company’s stock valued at $2,897,000 after purchasing an additional 116,700 shares during the period. CenterBook Partners LP boosted its stake in Avalo Therapeutics by 15.4% during the 3rd quarter. CenterBook Partners LP now owns 153,344 shares of the company’s stock valued at $2,351,000 after purchasing an additional 20,475 shares during the period. Finally, Squarepoint Ops LLC boosted its stake in Avalo Therapeutics by 624.9% during the 2nd quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock valued at $10,889,000 after purchasing an additional 507,960 shares during the period. Institutional investors own 87.06% of the company’s stock.
Key Stories Impacting Avalo Therapeutics
These are some of the AVTX stories that stood out recently:
- Positive Sentiment: Zacks says AVTX is technically oversold after losing 40.4% over four weeks, suggesting selling pressure may be tiring. It also cites analysts’ upward earnings-estimate revisions as a possible near-term catalyst for a trend reversal. Article: Here’s Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 Weeks
- Positive Sentiment: HC Wainwright raised its EPS forecasts for FY2026 and FY2027 and for several quarterly periods, indicating it expects losses to be narrower than previously estimated. Avalo Therapeutics analyst estimates
- Neutral Sentiment: Despite the improved forecasts, HC Wainwright’s rating remains Neutral. The short-interest report lists zero shares, so it does not indicate a meaningful short position based on the figures provided. Avalo Therapeutics market information
About Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions.
Featured Stories
- Five stocks we like better than Avalo Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
